C1R-neo細(xì)胞
生長(zhǎng)狀態(tài)： 懸浮生長(zhǎng)
細(xì)胞類型： B**細(xì)胞
是否是腫瘤細(xì)胞： 0
物種來源： 人
數(shù)量： 大量
ATCC Number： CRL-2369?
運(yùn)輸方式： 凍存運(yùn)輸
器官來源： 外周血
細(xì)胞形態(tài)： **樣
Designations: C1R-neo
Depositors: F Grumet
C1R-neo細(xì)胞Biosafety Level: 2 [Cells contain herpesvirus ]
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Homo sapiens
Morphology: lymphoblast
Source: Organ: peripheral blood
Cell Type: B lymphoblast; Epstein-Barr virus (EBV) transformed
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
DNA Profile (STR): Amelogenin: X
CSF1PO: 6,10
D13S317: 11,13
D16S539: 9,13
C1R-neo細(xì)胞D5S818: 10,13
D7S820: 7,12
THO1: 8
TPOX: 8
vWA: 17
Comments: C1R-neo is a stable transfectant cell line established in 1987 by transfection by electroporation of the C1R cell line with a modified neomycin drug-resistant eukaryotic vector, pSP65-Neo. The vector did not carry an insert. [38581]
C1R-neo does not secrete or express HLA B7.
C1R is a human B-cell lymphoblastoid line lacking surface HLA A and B antigens. C1R was derived from Hmy.2 B-LCL by gamma irradiation followed by selection for Class I monoclonal antibodies and complement. [23312]
C1R-neo may be used as a control for C1R-sB7 (CRL-2370), in CTL experiments and for producing control supernatants.
Propagation:C1R-neo細(xì)胞 ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension in fresh medium at 5 X 10(5) viable cells/ml.
Maintain cultures at cell concentrations between 5 X 10(5) and 2 X 10(6) viable cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005
recommended serum:ATCC 30-2020
parental cell line:ATCC CRL-1993
derived from same cell line:C1R-neo細(xì)胞ATCC CRL-2370
derived from same cell line:ATCC CRL-2371
References: 23312: Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569
38581: Grumet FC, et al. Soluble form of an HLA-B7 class I antigen specifically suppresses humoral alloimmunization. Hum. Immunol. 40: 228-234, 1994. PubMed: 7960967
38582: Hiraki DD, et al. Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization. Hum. Immunol. 40: 235-246, 1994. PubMed: 7960968
